The Catalogue of Prohibited Categories of Processing Trade in 2008 was recently introduced, adding 39 tens-digit high-pollution and high-environmental risk products; this year, the “2007 Second Catalogue of Prohibited Commodities in Processing Trade†was implemented. The involvement of some endangered species of animals and plants has received greater attention from the industry.
Recently, the Ministry of Commerce and the General Administration of Customs jointly promulgated the announcement No. 22 of 2008, and the Catalogue of Prohibited Categories of Processing Trade in 2008 (hereinafter referred to as the "2008 Catalogue") was implemented starting from April 5.
According to the website of the Ministry of Commerce, the new catalog is mainly based on the 2008 national import and export tariffs, and technical adjustments have been made to the previously published catalogue of commodity catalogs for the prohibition of processing trade; at the same time, 39 tens digits have been added according to the recommendations of relevant state agencies. High-pollution, high-risk commodities.
The reporter was informed in the interview that 39 new prohibited catalogues were added in this round, some of which involved the manufacture of pharmaceutical intermediates. However, due to the setting of a one-month buffer period and allowing signed contracts to be completed, the industry believes that the impact of this directory is limited. However, many varieties of endangered animals and plants in the "2007 Second Catalogue of Prohibited Commodity Products for Processing Trade" that began to be implemented this year have attracted much attention. For the first time, this catalogue includes Chinese-style medicines containing endangered animal and plant ingredients in the Catalogue of Prohibited Products.
The Catalogue of Forbidden Catalogues of Processing Trade has long been controversial, first starting in 2004, when products such as endangered animal skins were first banned from processing trade exports. According to the interpretation of this catalogue by the relevant national authorities, this catalogue is a related product banned from importing and exporting through processing trade. It is included in the prohibition of the import and export of processing trade and is not included in the goods prohibited by the state for import and export. Enterprises can still follow the general trade pattern. Develop import and export business.
However, the "2007 Second Catalogue of Prohibited Commodities in Processing Trade" that was implemented this year will extend the scope of prohibition to Chinese patent medicines, and it will still have some impact on some processing trade-oriented enterprises involving bear bile and terpenoid products. .
“There are impacts, but at present domestic exports of endangered ingredients containing Chinese medicines are very small and the export volume is also very small. At the same time, these products do not circulate as medicines in the major trading markets.†Executive Director of China Pharmaceutical Enterprise Management Association Vice President Yu Mingde told the reporter of the "Medicine Economic News".
At the same time, he pointed out that the contradiction between endangered species and traditional Chinese medicine has always existed, and animal and plant medicines that really belong to the endangered category should indeed be abandoned. What needs attention is that this is actually a difference between the national culture and the internationally recognized animal. China needs to do a lot of work to publicize and explain.
It is understood that there are not a few Chinese proprietary Chinese medicines that contain endangered animal components that are exported domestically. Among them, there are a variety of products including Pixianzhi, Angong Niuhuang Pills, Babaodan, Xihuang Pills, Liushen Pills, Shexiang Baoxin Pills, Huoxiang Jietong Ointment, Shangshi Baozheng Cream, and Yunnan Baiyao. In the past, the use of endangered animal and plant components as a Chinese herbal medicine has also caused controversy. Australia, the Philippines and other countries have seized a large number of Chinese medicines and related products suspected of containing endangered wild animal and plant components in their Chinese communities.
However, Yu Mingde stated that with the advancement of propaganda and interpretation work in recent years, conservationists of endangered animals and plants abroad have come to understand that protecting the right to life and animals and safeguarding people’s right to health can be taken into consideration. Take the bear as an example. The bears in domestic medicine are artificial breeding. The current number of bears has greatly increased.
When the customs code was refined In terms of plant extracts, the "2008 Catalogue" basically continued the 2007 version. Oleoresins extracted from endangered plants and other heterocyclic compounds containing only oxygen heteroatoms extracted from other endangered plants are still prohibited from processing trade. Last year, the hopes of the domestic plant extract companies to refine the customs code for extracts of plants were temporarily defeated. At that time, they hoped that the country would implement different customs export codes for products extracted from plants of wild endangered species and products grown by hand.
It is undeniable that with the increase in the demand for medicinal extracts in the world, the domestic wild medicinal plant resources have indeed suffered a certain destruction. Among the 398 species of endangered plants contained in the Chinese Plant Red Book, 168 species of medicinal plants account for 42%. At present, a total of 169 kinds of medicinal plants in China are listed in the Regulations on the Protection of Wild Medicinal Plant Resources, the International Convention on Endangered Species and Animals and the Regulations on the Protection of Wild Plants in the State.
The reporter learned from Liu Zhanglin, director of the Chinese medicine department of the Chinese Medicine and Health Products Chamber of Commerce, that because of policy restrictions, there are not many enterprises that currently do the processing trade of extracts of endangered species from plants. Most of the companies are doing artificial planting products. In regards to the customs code, he also frankly stated: “Because all exports are under the same customs code, they are still inseparable. Customs has some difficulty in distinguishing between planting and wild.â€
He said that the development of the plant extracts industry of the endangered species has had no impact on the species. There is currently no scientific research result. Taking Cordyceps as an example, the price is now selling so high. It is also a way for the local people to become rich. However, whether such collection intensity directly leads to the endangerment of this species is not yet clear. Domestically, this is also the case. Lack of assessment.
Zeng Jianguo, Hunan Province Traditional Chinese Medicine Extract Engineering Research Center, told reporters that the customs code was not refined at the end, indicating that the relevant departments are very cautious about this matter. Although hopes are lost, due to the continuation of the policy of the previous year, the impact on the plant extract industry is limited. "The plant extraction industry has grown bigger and the country should consider it," he said.
The artificially cultivated route Zeng Jianguo stated that at present, the country’s processing trade in extracts of medicinal plants such as ginkgo can be released if it can provide artificial planting certification.
The reporter learned that the state is currently strengthening the protection of endangered plants. Take the example of the Guangxi Traditional Chinese Medicine Modernization Industry Special Project “Guangxi Da Zong Road and Endangered and Scarce Chinese Traditional Medicine GAP Variety Breeding Base†currently undertaken by the Guangxi Medical Botanical Garden, the project will build “Guangxi Province’s Traditional Chinese Medicine GAP Germplasm Resources Preservation, Variety Breeding , quality management, and other three research centers and "Guang bean root, Millettia, Chinese wolfberry, red bud big glutinous" and other four GAP production demonstration bases. After the project is put into production, 10 million GAP high-quality medicinal plant seedlings and 400,000 medicinal animal seedlings can be bred every year. At present, such a base in China is still under construction.
"If it is endangered, it needs to be determined with changes in the objective situation. Artificial cultivation and artificial breeding to a certain extent, you can re-identify the endangered. This should cause the Chinese medicine industry's attention." Yu Mingde believes.
Recently, the Ministry of Commerce and the General Administration of Customs jointly promulgated the announcement No. 22 of 2008, and the Catalogue of Prohibited Categories of Processing Trade in 2008 (hereinafter referred to as the "2008 Catalogue") was implemented starting from April 5.
According to the website of the Ministry of Commerce, the new catalog is mainly based on the 2008 national import and export tariffs, and technical adjustments have been made to the previously published catalogue of commodity catalogs for the prohibition of processing trade; at the same time, 39 tens digits have been added according to the recommendations of relevant state agencies. High-pollution, high-risk commodities.
The reporter was informed in the interview that 39 new prohibited catalogues were added in this round, some of which involved the manufacture of pharmaceutical intermediates. However, due to the setting of a one-month buffer period and allowing signed contracts to be completed, the industry believes that the impact of this directory is limited. However, many varieties of endangered animals and plants in the "2007 Second Catalogue of Prohibited Commodity Products for Processing Trade" that began to be implemented this year have attracted much attention. For the first time, this catalogue includes Chinese-style medicines containing endangered animal and plant ingredients in the Catalogue of Prohibited Products.
The Catalogue of Forbidden Catalogues of Processing Trade has long been controversial, first starting in 2004, when products such as endangered animal skins were first banned from processing trade exports. According to the interpretation of this catalogue by the relevant national authorities, this catalogue is a related product banned from importing and exporting through processing trade. It is included in the prohibition of the import and export of processing trade and is not included in the goods prohibited by the state for import and export. Enterprises can still follow the general trade pattern. Develop import and export business.
However, the "2007 Second Catalogue of Prohibited Commodities in Processing Trade" that was implemented this year will extend the scope of prohibition to Chinese patent medicines, and it will still have some impact on some processing trade-oriented enterprises involving bear bile and terpenoid products. .
“There are impacts, but at present domestic exports of endangered ingredients containing Chinese medicines are very small and the export volume is also very small. At the same time, these products do not circulate as medicines in the major trading markets.†Executive Director of China Pharmaceutical Enterprise Management Association Vice President Yu Mingde told the reporter of the "Medicine Economic News".
At the same time, he pointed out that the contradiction between endangered species and traditional Chinese medicine has always existed, and animal and plant medicines that really belong to the endangered category should indeed be abandoned. What needs attention is that this is actually a difference between the national culture and the internationally recognized animal. China needs to do a lot of work to publicize and explain.
It is understood that there are not a few Chinese proprietary Chinese medicines that contain endangered animal components that are exported domestically. Among them, there are a variety of products including Pixianzhi, Angong Niuhuang Pills, Babaodan, Xihuang Pills, Liushen Pills, Shexiang Baoxin Pills, Huoxiang Jietong Ointment, Shangshi Baozheng Cream, and Yunnan Baiyao. In the past, the use of endangered animal and plant components as a Chinese herbal medicine has also caused controversy. Australia, the Philippines and other countries have seized a large number of Chinese medicines and related products suspected of containing endangered wild animal and plant components in their Chinese communities.
However, Yu Mingde stated that with the advancement of propaganda and interpretation work in recent years, conservationists of endangered animals and plants abroad have come to understand that protecting the right to life and animals and safeguarding people’s right to health can be taken into consideration. Take the bear as an example. The bears in domestic medicine are artificial breeding. The current number of bears has greatly increased.
When the customs code was refined In terms of plant extracts, the "2008 Catalogue" basically continued the 2007 version. Oleoresins extracted from endangered plants and other heterocyclic compounds containing only oxygen heteroatoms extracted from other endangered plants are still prohibited from processing trade. Last year, the hopes of the domestic plant extract companies to refine the customs code for extracts of plants were temporarily defeated. At that time, they hoped that the country would implement different customs export codes for products extracted from plants of wild endangered species and products grown by hand.
It is undeniable that with the increase in the demand for medicinal extracts in the world, the domestic wild medicinal plant resources have indeed suffered a certain destruction. Among the 398 species of endangered plants contained in the Chinese Plant Red Book, 168 species of medicinal plants account for 42%. At present, a total of 169 kinds of medicinal plants in China are listed in the Regulations on the Protection of Wild Medicinal Plant Resources, the International Convention on Endangered Species and Animals and the Regulations on the Protection of Wild Plants in the State.
The reporter learned from Liu Zhanglin, director of the Chinese medicine department of the Chinese Medicine and Health Products Chamber of Commerce, that because of policy restrictions, there are not many enterprises that currently do the processing trade of extracts of endangered species from plants. Most of the companies are doing artificial planting products. In regards to the customs code, he also frankly stated: “Because all exports are under the same customs code, they are still inseparable. Customs has some difficulty in distinguishing between planting and wild.â€
He said that the development of the plant extracts industry of the endangered species has had no impact on the species. There is currently no scientific research result. Taking Cordyceps as an example, the price is now selling so high. It is also a way for the local people to become rich. However, whether such collection intensity directly leads to the endangerment of this species is not yet clear. Domestically, this is also the case. Lack of assessment.
Zeng Jianguo, Hunan Province Traditional Chinese Medicine Extract Engineering Research Center, told reporters that the customs code was not refined at the end, indicating that the relevant departments are very cautious about this matter. Although hopes are lost, due to the continuation of the policy of the previous year, the impact on the plant extract industry is limited. "The plant extraction industry has grown bigger and the country should consider it," he said.
The artificially cultivated route Zeng Jianguo stated that at present, the country’s processing trade in extracts of medicinal plants such as ginkgo can be released if it can provide artificial planting certification.
The reporter learned that the state is currently strengthening the protection of endangered plants. Take the example of the Guangxi Traditional Chinese Medicine Modernization Industry Special Project “Guangxi Da Zong Road and Endangered and Scarce Chinese Traditional Medicine GAP Variety Breeding Base†currently undertaken by the Guangxi Medical Botanical Garden, the project will build “Guangxi Province’s Traditional Chinese Medicine GAP Germplasm Resources Preservation, Variety Breeding , quality management, and other three research centers and "Guang bean root, Millettia, Chinese wolfberry, red bud big glutinous" and other four GAP production demonstration bases. After the project is put into production, 10 million GAP high-quality medicinal plant seedlings and 400,000 medicinal animal seedlings can be bred every year. At present, such a base in China is still under construction.
"If it is endangered, it needs to be determined with changes in the objective situation. Artificial cultivation and artificial breeding to a certain extent, you can re-identify the endangered. This should cause the Chinese medicine industry's attention." Yu Mingde believes.
Electric Aroma Oil Diffuser,Home Scent Diffuser,Air Scent Diffuser,Easy Home Aroma Diffuser
Guangzhou Chiyang Scent Technology Co., Ltd. , https://www.gzdiffuserscent.com